Menu
Recruiting NCT07623785

Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health

No phase Interventional Healthy Aging Brain Health Cardiometabolic Health Normal Aging

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Lean Beef, Non-Beef Control.
Who it may be relevant to
Registry conditions: Healthy Aging, Brain Health, Cardiometabolic Health, Normal Aging. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

his study investigates whether eating lean beef every day can help support brain health and healthy aging in older adults. As people age, protecting memory and cognitive function becomes increasingly important. Lean beef is a rich source of essential nutrients-such as vitamin B12, iron, zinc, and creatine-that are known to support brain function. However, the direct biological effects of a beef-rich diet on brain health markers are not fully understood. In this study, researchers will recruit 20 generally healthy older adults (aged 65 and older) to participate in a dietary feeding trial. Participants will complete two separate 2-week dietary phases. During one phase, participants will consume 5.5 ounces (156 grams) of provided lean beef daily. During the other phase, they will consume an iso-caloric, protein-matched, non-beef control food daily. A two-week "washout" period, where participants return to their normal diets, will separate the two phases to ensure there are no overlapping effects. Researchers will collect blood, urine, stool, and saliva samples at the beginning and end of each 2-week dietary phase. These samples will be analyzed to see if the lean beef diet improves specific biological markers in the blood related to memory, nerve protection, and overall brain aging. Ultimately, the findings from this study will help determine if incorporating lean beef into a regular diet can be a natural, food-based strategy to help preserve neurological health in older adults.

Detailed description

Background and Rationale:

Cognitive decline and related dementias represent a growing public health crisis. While age and genetics are immutable risks, diet is a key modifiable factor for prevention and resilience. Lean beef provides a unique nutrient matrix-including vitamin B12, heme iron, zinc, selenium, creatine, and choline-that may support multiple aspects of brain structure and function. Recent advances in blood-based biomarkers now allow for the sensitive detection of neuropathological processes and neuroplasticity in response to lifestyle interventions. This project seeks to move beyond observational data to uncover the biological mechanisms that confer brain health by assessing the direct molecular impact of a dietary beef intervention.

Study Objectives:

The overarching goal of this study is to determine the impact of regular lean beef consumption on the molecular profile of brain health in healthy older adults. The primary aim is to quantify the within-person change in plasma phosphorylated tau-217 (p-tau217) following a 2-week lean beef intervention compared to a matched non-beef control. Secondary and exploratory aims include measuring within-person changes in the amyloid-beta 42/40 ratio (Aβ42/40) and Brain-Derived Neurotrophic Factor (BDNF), characterizing global shifts in the plasma lipidome, and exploring mechanisms of action via nutrient biomarkers.

Study Design:

The study is designed as a two-arm, randomized, controlled, crossover feeding trial. Twenty generally healthy adults (aged 65 years and older) will be block-randomized (1:1) to begin with either the intervention phase or the control phase.

Intervention Phase: Daily incorporation of 156 grams (5.5 oz) of lean beef for 14 days.

Control Phase: Daily incorporation of an iso-caloric, protein-matched non-beef control for 14 days.

A two-week washout period will separate the two phases to eliminate physiological carryover effects. Assignment of sequence will be randomized and counterbalanced to control for order and seasonal bias. Participants will maintain habitual eating patterns but will replace their daily protein sources with the study-provided food.

Methodology and Data Collection:

Clinical data and biological specimens will be collected at four distinct time points: the baseline and the conclusion of each 14-day dietary phase. At each clinical visit, fasted (12-hour) blood samples, as well as urine, stool, and saliva samples, will be collected. Basic anthropometric measurements, vital signs, and daily dietary records will also be obtained to monitor adherence and physical stability.

Outcome Evaluation and Analysis:

Targeted biomarkers of neurodegeneration and neuroplasticity (p-tau217, Aβ42/40, and BDNF) will be quantified using validated enzyme-linked immunosorbent assays (ELISA). Comprehensive untargeted lipidomic profiling will be conducted via Liquid Chromatography-Mass Spectrometry (LC-MS) workflows to identify lipid signatures associated with the intervention. Primary statistical analyses will utilize linear mixed-effects models to compare within-subject differences between the beef intervention and control conditions, adjusting for sequence and period effects. Appropriate statistical corrections will be applied for multiple comparisons and high-dimensional omics data.

Interventions

  • Other Lean Beef
    Participants will be provided with and instructed to consume 156 grams (5.5 ounces) of cooked lean beef daily for 14 days.
  • Other Non-Beef Control
    Participants will be provided with and instructed to consume an iso-caloric, macronutrient- and protein-matched non-beef control consisting of a mixture of cottage cheese and whey protein daily for 14 days.

Primary outcome measures

  • Change in Plasma Phosphorylated Tau-217 (p-tau217) Concentration [Time frame: Baseline (Day 0) and End of Intervention (Day 14) for each of the two dietary phases.]
  • Change in Plasma Amyloid-Beta 42/40 (Aβ42/40) Ratio [Time frame: Baseline (Day 0) and End of Intervention (Day 14) for each of the two dietary phases.]
Secondary outcome measures (2)
  • Shift in Plasma Lipidome Profile [Time frame: Baseline (Day 0) and End of Intervention (Day 14) for each of the two dietary phases.]
  • Change in Gut Microbiome Composition [Time frame: Baseline (Day 0) and End of Intervention (Day 14) for each of the two dietary phases.]

Eligibility criteria

Inclusion criteria

Adults aged 65 years and older.

Generally healthy with no acute illnesses.

Fluent in English.

Willing to consume lean beef and dairy products (cottage cheese and whey protein) daily during the intervention phases.

Willing to maintain current, habitual diet, physical activity levels, and body weight throughout the study.

Willing to fast for 12 hours prior to clinical visits and provide blood, urine, stool, and saliva samples.

Exclusion criteria

Diagnosed with Alzheimer's disease, Parkinson's disease, or other severe cognitive disorders.

History of gastrointestinal diseases (e.g., Crohn's disease, celiac disease) or major gastrointestinal surgery.

Uncontrolled diabetes, severe liver or kidney disease, or a recent cardiovascular event (within the past 6 months).

Allergies or severe intolerances to beef or dairy, or adherence to a strict vegetarian or vegan diet.

Body weight fluctuation of >5% within the past 3 months.

Use of systemic antibiotics within the 2 months prior to baseline.

Current heavy smoking or excessive alcohol consumption.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • South Dakota State University — Brookings

Identifiers

NCT: NCT07623785 · IRB-2026-101

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗